PMVP - PMV Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
6.12
+0.43 (+7.56%)
At close: 04:00PM EDT
6.12 0.00 (0.00%)
After hours: 04:02PM EDT
Stock chart is not supported by your current browser
Previous close5.69
Open5.71
Bid5.76 x 800
Ask6.50 x 900
Day's range5.62 - 6.26
52-week range3.84 - 17.77
Volume315,785
Avg. volume566,117
Market cap280.146M
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)-1.76
Earnings date07 Aug 2023 - 11 Aug 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.50
  • GlobeNewswire

    PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

    PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference taking place in Dana Point, California June 12-15, 2023. The company will also be availab

  • GlobeNewswire

    PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

    Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; next update is expected in 2H 2023Commenced enrollment in the combination arm of the PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab) PRINCETON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and developmen

  • Simply Wall St.

    We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • GlobeNewswire

    PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

    Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023Enrolled first patient in combination arm of the PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab)Cash, cash equivalents, and marketable securities of $243.5 million as of December 31, 2022 PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PMV

  • GlobeNewswire

    PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

    PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March. Cowen’s 43rd Annual Health Care Conference (March 6-8, 2023)Format:Tumor Diagnostic Development Corporate PanelDate:W

  • Zacks

    Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?

    The mean of analysts' price targets for PMV Pharmaceuticals, Inc. (PMVP) points to a 267.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • GlobeNewswire

    PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

    CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, taking place November 29 – December 1, 2022. The company will al

  • GlobeNewswire

    PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

    Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA® (pembrolizumab) on track to initiate in 2022 Biotech industry veteran Dr. Carol Gallagher appointed to Board of Directors CRANBURY, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology com

  • GlobeNewswire

    PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

    CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Boar

  • Zacks

    PMV Pharmaceuticals, Inc. (PMVP) Upgraded to Buy: Here's What You Should Know

    PMV Pharmaceuticals, Inc. (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

    Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutationEntered into a clinical collaboration with Merck to evaluate PC14586 in combination with KEYTRUDA®; study to initiate in Q4 2022 CRANBURY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” Nasdaq: PMVP), a precision oncology company pioneering the discovery and developm

  • GlobeNewswire

    PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

    Combination trial to be initiated in Q4 2022CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada) to evaluate PC14586, a first-in-class precision oncology small molecule inve

  • GlobeNewswire

    PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

    Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1 Partial responses observed across six distinct tumor typesData featured as an oral presentation at ASCO; Company to host investor event via webcast today at 6:30 pm CDT to review data presented CRANBURY, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap